BC Innovations | Jul 18, 2019
Emerging Company Profile

Neoleukin emerges with a de novo approach to improving biologics

With a platform to design proteins from scratch, Neoleukin is making a new class of biologics that resemble their endogenous protein counterparts in structure, but not in sequence. The strategy gives the company a clean...
BC Week In Review | Mar 1, 2019
Financial News

Syncona leads CHF35M A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round on Feb. 26 to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC)...
BC Extra | Feb 26, 2019
Financial News

Syncona leads CHF35 million A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round Tuesday to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC) is leading...
BC Week In Review | Feb 15, 2019
Company News

Clinigen adds U.S. rights to Proleukin

Clinigen Group plc (LSE:CLIN) jumped 134.5p (18%) to 872p on Feb. 13 after the U.K. specialty pharma said it will acquire U.S. rights to Proleukin aldesleukin from Novartis AG (NYSE:NVS; SIX:NOVN), giving Clinigen worldwide rights...
BC Extra | Feb 13, 2019
Company News

Clinigen adds U.S. rights to Proleukin

Clinigen Group plc (LSE:CLIN) jumped 134.5p (18%) to 872p on Wednesday after the U.K. specialty pharma said it will acquire U.S. rights to Proleukin aldesleukin from Novartis AG (NYSE:NVS; SIX:NOVN), giving Clinigen worldwide rights to...
BC Week In Review | Nov 16, 2018
Financial News

Synthorx proposes $100M IPO ahead of synthetic IL-2 clinical testing

Synthetic biology company Synthorx Inc. (La Jolla, Calif.) proposed to raise $100 million in a NASDAQ IPO, according to an SEC filing from Nov. 13. Synthorx is using synthetic biology to develop a pipeline of...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
BC Innovations | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased...
BC Week In Review | May 9, 2016
Clinical News

JTCR016: Phase I/II data

Top-line data from 3 patients with WT1-expressing stage III or IV NSCLC or mesothelioma in an open-label, dose-escalation, U.S. Phase I/II trial showed that a single IV dose of JTCR016 led to 1 partial response...
BC Week In Review | May 2, 2016
Clinical News

Entinostat: Phase I/II data

Top-line data from 37 evaluable patients with metastatic clear cell RCC who have completed one 84-day cycle in the Phase II portion of an open-label, U.S. Phase I/II trial showed that oral entinostat every 2...
Items per page:
1 - 10 of 127